Ozempic launched in India as Novo Nordisk rolls out weekly diabetes drug
Novo Nordisk has launched its once-weekly diabetes and weight-management drug Ozempic in India. The semaglutide-based GLP-1 agonist improves glycaemic control, supports weight loss and may reduce cardiovascular and kidney risks. Prices start at Rs 8,800 per month for the lowest dose
Hyderabad: Novo Nordisk on Friday launched its blockbuster anti-diabetic and anti-obesity drug Ozempic in India. The drug is a once-weekly GLP-1 Receptor Agonist (GLP-1 RA) indicated as an adjunct to diet and exercise for adults living with uncontrolled Type 2 Diabetes Mellitus (T2DM).
Ozempic’s active ingredient, semaglutide, works as a GLP-1 receptor agonist to help improve glycaemic control and reduce HbA1c and acts on areas of the brain that control hunger and regulate food intake, supporting weight-loss benefits for those with T2DM.
The company claimed that clinical trials demonstrate the drug’s ability to provide additional lowering of cardiovascular events and protection against chronic kidney disease progression. The drug is suitable for adults with HbA1c levels of 7 or more, including those with high cardiovascular risk or established cardiovascular disease.
“Ozempic offers Indian doctors an effective treatment choice. It is all delivered through a simple, easy-to-use pen device,” Vikrant Shrotriya, Managing Director, Novo Nordisk India.
Novo Nordisk has set the price of Ozempic’s lowest 0.25 mg dose at Rs 2,200 per week or Rs 8,800 per month. The 0.5 mg dose has been priced at Rs 10,170 per month, while the highest 1 mg dose will cost Rs 11,175 per month.
